Adipose Tissue Transfer for Moderate Breast Cancer Conservative Treatment Sequella

NCT ID: NCT01035268

Last Updated: 2018-08-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

196 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-02-08

Study Completion Date

2017-02-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a phase III randomized multi-center study of equivalence comparing the radiological follow-up for patients benefiting from the correction of the esthetical relapse of the preservative treatment by fatty transfer compared with a simple supervision.

It is planned that 440 patients participate in this study which plans to compare 2 groups of patients: a group of patients which will benefit from the surgical treatment by transfer of fatty tissue and a group of patients under simple supervision.

follow-up consultations are planned in 10 in 45 days post-surgery then at 3 months, 6 months, 12 months and 5 years to look for the expected unwanted effects in relation with the surgery but also to estimate the impact of the fatty transfer on the rate of local and\\or from a distance relapse.

During these consultations, the surgeon and the patient will also estimate the cosmetic result of the surgery thanks to a questionnaire of cosmetic evaluation and to standardized photos.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

surgery by fatty tissue transfer

Group Type EXPERIMENTAL

fatty tissue transfer

Intervention Type PROCEDURE

It will be proceeded to aspiration of the fat at the level of the natural steatomeries (hip, stomach), then in a transfer of the fat prepared in the breast by following the standardized protocol.

simple supervision

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

fatty tissue transfer

It will be proceeded to aspiration of the fat at the level of the natural steatomeries (hip, stomach), then in a transfer of the fat prepared in the breast by following the standardized protocol.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* History of breast cancer treated by conservative surgery .
* Normal inclusion radiological assessment normal (ACR1 or ACR2)
* Moderate Deformations (Type I and II of the classification of Clough).
* Delay with regard to the end of the radiotherapy superior or equal to one-year-old.
* Moderated radio-dystrophies (\< Grade 2 of the score LENT/SOMA).
* Signature of the informed consent
* Patient benefiting from social security
* Patient of more than 18 years old

Exclusion Criteria

* Abnormal radiological assessment (ACR3, ACR4 or ACR5)
* Absence of fatty excess .
* radio surgical relapses with vast fibroses of the breast (\> Grade 2 of the score LENT/SOMA).
* Patient under 18 years old.
* administrative difficulties: impossibility to provide enlightened information to the patient, the refusal to sign the consent .
* pregnant women or breast feeding women
* patient under legal guardianship
* bilateral breast cancer regardless histologic type.
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Institut Claudius Regaud

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ignacio GARRIDO, MD

Role: PRINCIPAL_INVESTIGATOR

Institut Claudius Regaud

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU de Besançon

Besançon, , France

Site Status

Clinique Saint Antoine

Bois-Guillaume, , France

Site Status

CHU Pellegrin

Bordeaux, , France

Site Status

Institut Bergonie

Bordeaux, , France

Site Status

Pole de Sante de Leonard de Vinci

Chambray-lès-Tours, , France

Site Status

Hopital Henri Mondor

Créteil, , France

Site Status

Centre Hospitalier La Croix Rousse

Lyon, , France

Site Status

Hopital Edouard Herriot

Lyon, , France

Site Status

CHR Marseille Conception

Marseille, , France

Site Status

Institut Paoli Calmettes

Marseille, , France

Site Status

Centre Val d'Aurelle

Montpellier, , France

Site Status

Clinique Brétéché

Nantes, , France

Site Status

INSTITUT CURIE - Site Paris

Paris, , France

Site Status

Hopital Saint Louis

Paris, , France

Site Status

Centre Eugene Marquis

Rennes, , France

Site Status

Centre Henri Becquerel

Rouen, , France

Site Status

INSTITUT CURIE - René Huguenin

Saint-Cloud, , France

Site Status

INSTITUT DE CANCEROLOGIE DE L'OUEST - Centre René Gauducheau

Saint-Herblain, , France

Site Status

Hôpitaux Universitaires de Strasbourg

Strasbourg, , France

Site Status

CHU Rangueil

Toulouse, , France

Site Status

Institut Claudius Regaud

Toulouse, , France

Site Status

Centre Alexis Vautrin

Vandœuvre-lès-Nancy, , France

Site Status

Institut Gustave Roussy

Villejuif, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

08 SEIN 08

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Delayed-Immediate Breast Reconstruction
NCT00473122 COMPLETED PHASE2